On November 10, 2026, Oura agreed to acquire Counsel Health, an AI-native primary care company, for $625 million in cash. The deal, announced alongside Oura's quarterly results, is the largest and most consequential move yet in the wearable industry's long drift from tracking health to delivering healthcare.
Counsel Health combines a chat-based medical AI with access to licensed, board-certified physicians who can diagnose, prescribe and refer. Oura's ring already collects continuous biometric data — sleep, heart rate, temperature, activity — from more than six million members. The acquisition joins the two halves: the device that notices something is wrong, and the clinician who can do something about it, inside the same app. The transaction is expected to close before the end of the calendar year, subject to customary closing conditions.
A Partnership Turned Into Ownership
The two companies were already working together. Counsel's medical AI was integrated into the Oura app in June 2026, available through the Oura Labs section, after a partnership that began in May. The acquisition converts a feature into a business line. Roughly 70 Counsel employees will join Oura, and Counsel founder and chief executive Dr. Muthu Alagappan will become Oura's chief clinical AI officer. Counsel will continue serving its own enterprise partners outside Oura's user base.
The price is striking in context. Counsel raised a $25 million Series A about a year ago, led by Andreessen Horowitz and GV, and PitchBook estimates its total funding at roughly $36 million. Oura is paying about 17 times what the startup raised. That multiple reflects how scarce Counsel's asset is: a working clinical AI paired with a real physician network, already integrated into a consumer health product at scale.
Oura can afford it. The company reported preliminary, unaudited revenue of $533 million for the fiscal fourth quarter ended September 30, 2026, up 153% year over year, with $87 million in adjusted EBITDA. Fiscal 2026 revenue was approximately $1.75 billion, up 92%. Those are the numbers of a hardware company that has already crossed into consumer-health scale — and they explain why Oura is spending on services rather than more sensors.
Why a Ring Maker Is Buying a Doctor
The strategic logic is the shift from data to action. A wearable that tells you your heart rate variability is low is interesting. A wearable that notices the pattern, asks about your symptoms, and connects you to a doctor who can order a test or adjust a prescription is a healthcare service. The first is a gadget business with hardware margins and replacement cycles. The second is a recurring service business with a much larger addressable market.
The timing also matters. Just weeks before the announcement, Oura postponed an initial public offering of up to $2.2 billion indefinitely, citing uncertainty in the IPO market. A company that delays going public often uses the extra private time to strengthen its story. Buying a clinical capability — and the revenue and retention that may come with it — is a way to arrive at the public markets as a healthcare company rather than a device company, with a valuation to match.
There are real risks. Neither company has said what a Counsel doctor visit will cost inside the Oura app, or whether it will be part of the existing subscription or a separate add-on. Clinical AI brings regulatory scrutiny, liability questions and data-privacy obligations that a consumer device company has not faced at this scale. And the service is explicitly not for emergencies. Oura must now run a medical operation, not just ship hardware.
What It Means for Health-Tech Founders and Investors
For founders, the deal reframes the wearable opportunity. The winning position may no longer be the best sensor; it may be the best loop between sensing and care. Startups building clinical AI, remote monitoring, chronic-care management and AI triage now have a large, well-funded acquirer actively buying in their space — and a template for how a device company values a care capability.
For investors, the deal is a reminder that health-tech value is migrating toward companies that control both the data and the clinical response. A device without a care pathway is a dashboard. A care pathway without continuous data is blind. The companies that own both can charge for outcomes rather than hardware, and that is where the multiples live.
The broader lesson extends beyond wearables. In every category where AI can observe a problem, the next step is owning the fix. Oura just paid $625 million to own its fix.
Angeled.com connects founders with investors.
The Verge, via iTechPost and Unite.AI coverage, November 10-11, 2026
Reuters, via Vocemundi, November 11, 2026
TechCrunch and STAT News, via Dealroom, November 10, 2026
Read Next
What a Reported $15B Raise at a $1.25T Valuation Would Mean for OpenAI — and Everyone Else
AlphaGenome 2 and the New Tooling Layer for Biotech Founders
Big Law Is Now Paying Lawyers to Learn AI — and That Changes Legal Tech
Biotech's $348 Million Week: Brain Drugs, Radiopharma and Gene Therapy
Databricks' Always-On Genie and the End of the Chatbot Era
Gemini Decision 1: Google's AI That Answers Instead of Chatting



